Innovation Pharmaceuticals Inc (IPIX)

[DaubersUP]

Something smells more like a cat with you and less lemon. I can't put my finger on it. However, everyone has an opinion right.

First I do want to point out: that verbiage is in all filings regarding going concern - first quote. The second with the specific date is a fact. they have stated their plan of operations in the near term and to be honest it is busting at the seam on how much they plan to accomplish. That is what it says.........they need additional funding to support the current "OPERATING PLAN" and they need that financing by end of quarter to move forward with all of these trials they have laid out in PR's over the past 6 months.

The planned oral Brilacidin clinical trial builds on recently released data showing in simulated gastric fluid testing very minimal degradation of Brilacidin across 4 hours, suggesting Brilacidin likely would not be subject to rapid breakdown once in the stomach.

Brilacidin has been successfully evaluated in clinical trials in oral mucositis, inflammatory bowel disease and serious skin infections, with planned extension into dermatological diseases.

Given Brilacidin is administered as a convenient oral rinse, with plans to package it in an easily transportable sachet form, the Company believes it would be attractive both to doctors and patients—likely translating to widespread and rapid market adoption should Brilacidin oral rinse gain regulatory approval.

At that time, we intend to focus our resources on the next stages of development for Brilacidin, notably dermatologic indications, and Kevetrin as a novel anti-cancer agent to build upon the completed studies.”

Innovation Pharmaceuticals is preparing to seek scientific advice from the European Medicines Agency to round out European Union program requirements for Phase 3 clinical trials.

“Our interactions with the FDA have been highly collaborative and constructive, providing us with clear guidance to help inform our Phase 3 development plans,”

Plans include developing Brilacidin in an oral dosage form to treat more complex cases of IBD, such as Ulcerative Colitis and Crohn’s Disease.

I can go on and on --- but a lot of plans and money needed. So to meet their current operating plans of all of the above, money is needed for sure. I would not put this doom and gloom March 31st they shut the doors though. They will just continue to search and negotiate with partners to find that perfect fit and trials will be delayed until they do so. Good thing they are talking to several suitors and IMO we will have multiple partners, starting with international suitors.

Good luck